Receptos to Present at Jefferies 2015 Global Healthcare Conference
28 mai 2015 08h00 HE
|
Receptos, Inc.
SAN DIEGO, May 28, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
Receptos Announces Oral Plenary Presentation of TOUCHSTONE Phase 2 Induction Data at Digestive Disease Week 2015
15 mai 2015 08h00 HE
|
Receptos, Inc.
SAN DIEGO, May 15, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
Receptos to Present at UBS Global Healthcare Conference
14 mai 2015 08h00 HE
|
Receptos, Inc.
SAN DIEGO, May 14, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
Receptos to Present at Bank of America Merrill Lynch 2015 Healthcare Conference
07 mai 2015 08h00 HE
|
Receptos, Inc.
SAN DIEGO, May 7, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
Receptos Provides Business Update and Reports First Quarter 2015 Financial Results
05 mai 2015 16h01 HE
|
Receptos, Inc.
- Positive Phase 2 induction and maintenance results for TOUCHSTONE trial of ozanimod (formerly RPC1063) in Ulcerative Colitis (UC) support broad development program in UC, Crohn's Disease -
-...
Receptos to Hold First Quarter 2015 Results Conference Call
29 avr. 2015 08h00 HE
|
Receptos, Inc.
SAN DIEGO, April 29, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will...
Receptos Reports Positive Results for the Maintenance Period of the Phase 2 TOUCHSTONE Trial of Ozanimod in Ulcerative Colitis
16 avr. 2015 08h00 HE
|
Receptos, Inc.
- Study met all efficacy endpoints with statistical significance for patients on 1 mg dose after 32 weeks of treatment -
- Safety data are consistent with the favorable profile observed in prior...
Receptos Completes Enrollment of RADIANCE Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis
01 avr. 2015 08h00 HE
|
Receptos, Inc.
SUNBEAM Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis Continues to Enroll According to Plan; Overall Phase 3 Program on Track to be Completed in 1H 2017
Receptos Well Capitalized to...
Receptos to Present at Barclays Global Healthcare Conference
09 mars 2015 08h00 HE
|
Receptos, Inc.
SAN DIEGO, March 9, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
Receptos Provides Development Updates and Reports Fourth Quarter and Year End 2014 Financial Results
03 mars 2015 16h01 HE
|
Receptos, Inc.
- Positive Phase 2 induction results for TOUCHSTONE trial of ozanimod (formerly RPC1063) in Ulcerative Colitis (UC) support initiation of broad development program in UC, Crohn's Disease -
- Both...